CN113795506A - 用于治疗CD1a阳性癌症的CAR T细胞 - Google Patents

用于治疗CD1a阳性癌症的CAR T细胞 Download PDF

Info

Publication number
CN113795506A
CN113795506A CN202080028333.9A CN202080028333A CN113795506A CN 113795506 A CN113795506 A CN 113795506A CN 202080028333 A CN202080028333 A CN 202080028333A CN 113795506 A CN113795506 A CN 113795506A
Authority
CN
China
Prior art keywords
cd1a
cell
cells
domain
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080028333.9A
Other languages
English (en)
Chinese (zh)
Inventor
巴布罗·梅内德斯·布扬
迭戈·桑切斯·马丁内斯
克拉拉·布埃诺·乌鲁兹
弗朗西斯科·古铁雷斯·阿古埃拉
海莉亚·洛卡-霍
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Germanic Trias Ephol Institute Of Health Sciences Foundation Igtp
Institute Of Advanced Studies Of Catalonia Icrea
Fundacio Institut de Recerca contra la Leucemia Josep Carreras
Original Assignee
Germanic Trias Ephol Institute Of Health Sciences Foundation Igtp
Institute Of Advanced Studies Of Catalonia Icrea
Fundacio Institut de Recerca contra la Leucemia Josep Carreras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Germanic Trias Ephol Institute Of Health Sciences Foundation Igtp, Institute Of Advanced Studies Of Catalonia Icrea, Fundacio Institut de Recerca contra la Leucemia Josep Carreras filed Critical Germanic Trias Ephol Institute Of Health Sciences Foundation Igtp
Priority to CN202410679216.9A priority Critical patent/CN118436770A/zh
Publication of CN113795506A publication Critical patent/CN113795506A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4213—CD74, Ii, MHC class II invariant chain or MHC class II gamma chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4224—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202080028333.9A 2019-02-14 2020-02-13 用于治疗CD1a阳性癌症的CAR T细胞 Pending CN113795506A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202410679216.9A CN118436770A (zh) 2019-02-14 2020-02-13 用于治疗CD1a阳性癌症的CAR T细胞

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19382104.8 2019-02-14
EP19382104.8A EP3696191A1 (en) 2019-02-14 2019-02-14 Car t-cells for the treatment of cd1a-positive cancer
PCT/EP2020/053769 WO2020165350A1 (en) 2019-02-14 2020-02-13 Car t-cells for the treatment of cd1a-positive cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202410679216.9A Division CN118436770A (zh) 2019-02-14 2020-02-13 用于治疗CD1a阳性癌症的CAR T细胞

Publications (1)

Publication Number Publication Date
CN113795506A true CN113795506A (zh) 2021-12-14

Family

ID=65685281

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202080028333.9A Pending CN113795506A (zh) 2019-02-14 2020-02-13 用于治疗CD1a阳性癌症的CAR T细胞
CN202410679216.9A Pending CN118436770A (zh) 2019-02-14 2020-02-13 用于治疗CD1a阳性癌症的CAR T细胞

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202410679216.9A Pending CN118436770A (zh) 2019-02-14 2020-02-13 用于治疗CD1a阳性癌症的CAR T细胞

Country Status (8)

Country Link
US (2) US12215158B2 (https=)
EP (2) EP3696191A1 (https=)
JP (2) JP7590737B2 (https=)
CN (2) CN113795506A (https=)
AU (1) AU2020222239B2 (https=)
CA (1) CA3128955A1 (https=)
MX (1) MX2021009798A (https=)
WO (1) WO2020165350A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer
KR20230084212A (ko) 2020-10-09 2023-06-12 화이자 인코포레이티드 CD1a 항체 및 그의 용도
EP4347045A1 (en) * 2021-05-26 2024-04-10 Oxford University Innovation Limited Antibodies
IT202100027929A1 (it) * 2021-11-02 2023-05-02 Univ Degli Studi Magna Graecia Di Catanzaro Un nuovo anticorpo bispecifico asimmetrico(UMG2/CD1a-CD3e) per il trattamento immunologico della forma corticale di leucemia linfoblastica acuta T (T-ALL) pediatrica e dell’adulto
EP4234582A1 (en) * 2022-02-28 2023-08-30 Onechain Immunotherapeutics SL Humanized cd1a targeting moiety for the treatment of cd1a-positive cancer
CN119384436A (zh) * 2022-02-28 2025-01-28 单链免疫治疗有限公司 用于治疗CD1a阳性癌症的人源化CD1a靶向部分
GB202217923D0 (en) * 2022-11-29 2023-01-11 Univ Oxford Innovation Ltd Antibodies
EP4417623A1 (en) * 2023-02-15 2024-08-21 Fundació Institut de Recerca Contra la Leucèmia Josep Carreras Ccr9 targeting moiety for the treatment of ccr9-positive cancer
EP4667494A3 (en) * 2023-10-26 2026-03-04 Fundación Instituto de Investigación Sanitaria Fundación Jiménez Díaz Car t-cells against cd79b for the treatment of non-hodgkin lymphoma
CN119685260B (zh) * 2024-12-17 2026-01-13 上海交通大学医学院附属瑞金医院 一种具有新型穿膜区的嵌合抗原受体t细胞及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030884A2 (en) * 2007-09-03 2009-03-12 Cambridge Enterprise Limited Mannosylated butyrophilin tumour markers
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EP3696191A1 (en) * 2019-02-14 2020-08-19 Fundación Instituto de Investigación contra la Leucemia Josep Carreras (IJC) Car t-cells for the treatment of cd1a-positive cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009030884A2 (en) * 2007-09-03 2009-03-12 Cambridge Enterprise Limited Mannosylated butyrophilin tumour markers
CN107708741A (zh) * 2015-06-12 2018-02-16 免疫医疗公司 用嵌合抗原受体(car)构建体和表达car构建体的t细胞(car‑t)或nk细胞(car‑nk)进行的疾病疗法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
D SANCHEZ-MARTINEZ 等: ""Adoptive Cellular Immunotherapy using CD1a CART-cells for Treatment of CorticalPediatric T-Cell Acute Lymphoblastic Leukemia"", 《KLINISCHE PAEDIATRIE》, vol. 230, no. 03, pages 174 *
DIEGO SANCHEZ-MARTINEZ 等: ""Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia"", 《BLOOD》, vol. 133, no. 21, pages 2291 - 2304, XP055606731 *
PABLO MENENDEZ 等: ""Adoptive Cellular Immunotherapy Using Cd1a CART-Cells for Cortical T-Cell Acute Lymphoblastic Leukemia"", 《EXPERIMENTAL HEMATOLOGY》, vol. 64, pages 437 *

Also Published As

Publication number Publication date
WO2020165350A1 (en) 2020-08-20
US12215158B2 (en) 2025-02-04
JP2025024031A (ja) 2025-02-19
AU2020222239B2 (en) 2024-12-05
JP7590737B2 (ja) 2024-11-27
CN118436770A (zh) 2024-08-06
EP3924374A1 (en) 2021-12-22
JP2022520455A (ja) 2022-03-30
US20220143085A1 (en) 2022-05-12
MX2021009798A (es) 2021-11-17
CA3128955A1 (en) 2020-08-20
US20260116982A1 (en) 2026-04-30
EP3696191A1 (en) 2020-08-19
AU2020222239A1 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
US20260116982A1 (en) Car t-cells for the treatment of cd1a-positive cancer
JP7451627B2 (ja) キメラ受容体及びその使用方法
JP7352473B2 (ja) がん細胞を標的化するキメラ抗原受容体のための方法および組成物
KR20240021153A (ko) Nkp46 및 cd38를 표적으로 하는 이중 특이적 항체 및 이의 사용 방법
US12509525B2 (en) CAR T-cells against BCMA for the treatment of multiple myeloma
WO2023200873A2 (en) Chimeric antigen receptor compositions and methods of using the same
CN115843255B (zh) 用于治疗b细胞型急性淋巴细胞白血病(b-all)的cd22靶向部分
KR20230121114A (ko) 암의 치료를 위한 다중특이적 항체
EP4378953A1 (en) Cd229 targeting moiety for the tratment of cd229 positive cancer
EP4417623A1 (en) Ccr9 targeting moiety for the treatment of ccr9-positive cancer
TWI790193B (zh) 調控免疫反應之方法及抗體
HK40116152A (zh) 用於治疗cd1a阳性癌症的car t细胞
KR20240153597A (ko) CD1a-양성 암을 치료하기 위한 인간화된 CD1a 표적화 모이어티
HK40126667A (zh) 嵌合抗原和t细胞受体及使用的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20211214

WD01 Invention patent application deemed withdrawn after publication